Pershing Edward
Reporting owner on Forms 3, 4 and 5, CIK 1689739.
Pershing Edward reported on 1 issuer in 6 filings, the latest a Form 4 filed 2026-11-16.
Issuers
| Issuer | Roles in the latest filing | Filings | Last filed |
|---|---|---|---|
| PROVECTUS BIOPHARMACEUTICALS, INC. CIK 315545 | director, officer (CEO), 10% owner | 6 | 2026-11-16 |
Transactions and holdings
Every row of the person's Forms 3, 4 and 5, newest first, with the price and the amount owned after the row as filed.
| Security | Date | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| PVCT · PROVECTUS BIOPHARMACEUTICAL…8% Unsecured Convertible Promissory Note, derivative | 2026-11-13 | M exercised | - | $0 | Form 4 | |
| PVCT · PROVECTUS BIOPHARMACEUTICAL…Series D-1 Convertible Preferred Stock, derivative | 2026-11-13 | M exercised | +11,328 | $0 | 3,055,221 | Form 4 |
| PVCT · PROVECTUS BIOPHARMACEUTICAL…8% Unsecured Convertible Promissory Note, derivative | 2026-11-06 | M exercised | - | $0 | Form 4 | |
| PVCT · PROVECTUS BIOPHARMACEUTICAL…Series D-1 Convertible Preferred Stock, derivative | 2026-11-06 | M exercised | +13,216 | $0 | 3,043,893 | Form 4 |
| PVCT · PROVECTUS BIOPHARMACEUTICAL…8% Unsecured Convertible Promissory Note, derivative | 2026-10-30 | M exercised | - | $0 | Form 4 | |
| PVCT · PROVECTUS BIOPHARMACEUTICAL…Series D-1 Convertible Preferred Stock, derivative | 2026-10-30 | M exercised | +24,544 | $0 | 3,030,677 | Form 4 |
| PROVECTUS BIOPHARMACEUTICAL… 8% Unsecured Convertible Promissory Note, derivative | 2026-10-23 | M exercised | - | $0 | Form 4 | |
| PROVECTUS BIOPHARMACEUTICAL… Series D-1 Convertible Preferred Stock, derivative | 2026-10-23 | M exercised | +7,599 | $0 | 3,006,133 | Form 4 |
| PROVECTUS BIOPHARMACEUTICAL… 8% Unsecured Convertible Promissory Note, derivative | 2026-10-10 | M exercised | - | $0 | Form 4 | |
| PROVECTUS BIOPHARMACEUTICAL… Series D-1 Convertible Preferred Stock, derivative | 2026-10-10 | M exercised | +22,609 | $0 | 2,998,534 | Form 4 |
| PROVECTUS BIOPHARMACEUTICAL… 8% Unsecured Convertible Promissory Note, derivative | 2026-10-03 | M exercised | - | $0 | Form 4 | |
| PROVECTUS BIOPHARMACEUTICAL… Series D-1 Convertible Preferred Stock, derivative | 2026-10-03 | M exercised | +13,216 | $0 | 2,975,925 | Form 4 |
Filings
The person's Forms 3, 4 and 5, and any 13D or 13G naming it.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| Form 4 0001493152-26-052537 | PROVECTUS BIOPHARMACEUTICALS, INC. | 2026-11-16 | ||
| Form 4 0001493152-26-050663 | PROVECTUS BIOPHARMACEUTICALS, INC. | 2026-11-09 | ||
| Form 4 0001493152-26-049383 | PROVECTUS BIOPHARMACEUTICALS, INC. | 2026-10-30 | ||
| Form 4 0001493152-26-048321 | PROVECTUS BIOPHARMACEUTICALS, INC. | 2026-10-23 | ||
| Form 4 0001493152-26-046701 | PROVECTUS BIOPHARMACEUTICALS, INC. | 2026-10-13 | ||
| Form 4 0001493152-26-045713 | PROVECTUS BIOPHARMACEUTICALS, INC. | 2026-10-05 |